Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$8 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.3
Industry P/E
--
EV/EBITDA
-1
Div. Yield
0 %
Debt to Equity
0
Book Value
$4
EPS
$-2.7
Face value
--
Shares outstanding
3,677,935
CFO
$-77.48 Mln
EBITDA
$-93.52 Mln
Net Profit
$-105.22 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kiora Pharmaceuticals (KPRX)
| -1.0 | -6.7 | -1.0 | -35.2 | -59.8 | -74.5 | -59.6 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Kiora Pharmaceuticals (KPRX)
| -40.3 | -29.6 | -84.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kiora Pharmaceuticals (KPRX)
|
2.0 | 7.5 | 0.0 | -10.8 | -- | -51.7 | -- | 0.3 |
| 9.1 | 2,179.2 | 510.2 | 146.9 | 37.2 | 35.6 | 15.5 | 4.6 | |
| 12.7 | 3,812.0 | 3,018.8 | 72.1 | 12.6 | -80 | 54.3 | 86.1 | |
| 171.8 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 74.5 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.0 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.5 | 11,237.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.7 | 2.9 | |
| 23.1 | 11,653.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.3 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small... molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. Address: 332 Encinitas Boulevard, Encinitas, CA, United States, 92024 Read more
President, CEO & Director
Dr. Brian M. Strem Ph.D.
President, CEO & Director
Dr. Brian M. Strem Ph.D.
Headquarters
Encinitas, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Kiora Pharmaceuticals Inc (KPRX) is $1.95 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Kiora Pharmaceuticals Inc (KPRX) has given a return of -59.82% in the last 3 years.
Since, TTM earnings of Kiora Pharmaceuticals Inc (KPRX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.73
|
0.49
|
|
2024
|
3.67
|
0.51
|
|
2023
|
-0.04
|
0.09
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Kiora Pharmaceuticals Inc (KPRX) are Rs 4.18 and Rs 1.76 as of 02-Apr-2026.
Kiora Pharmaceuticals Inc (KPRX) has a market capitalisation of $ 8 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Kiora Pharmaceuticals Inc (KPRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.02
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.